GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

2026-01-20 | original

read original get Food allergy treatments → more articles

The drugmaker said it agreed to pay RAPT Therapeutics shareholders $58 per share, with $1.9 billion upfront investment in cash.

Explore topics: agreed agreed pay billion billion upfront cash